Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CORBF
Global Cord Blood
$1.50
$1.03
$0.25
$2.00
$182.33M-0.66123,446 shs14,959 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$19.47
+1.6%
$18.14
$15.45
$35.84
$553.19M1.03419,891 shs430,423 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$19.57
+0.3%
$19.89
$14.57
$25.11
$594.26M1.06285,879 shs162,180 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$12.84
-8.6%
$10.29
$3.99
$15.84
$638.54M2.421.07 million shs2.63 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CORBF
Global Cord Blood
0.00%+19.05%+50.00%+87.50%+25.00%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
+1.62%+2.96%+20.93%-3.13%-9.19%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+0.26%-3.60%-3.64%+16.14%-4.02%
LifeMD, Inc. stock logo
LFMD
LifeMD
-8.61%-14.74%+11.36%+129.29%+89.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CORBF
Global Cord Blood
N/AN/AN/AN/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2.4996 of 5 stars
3.53.00.00.01.92.50.0
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
4.0606 of 5 stars
2.34.00.04.12.63.30.6
LifeMD, Inc. stock logo
LFMD
LifeMD
1.3628 of 5 stars
1.54.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CORBF
Global Cord Blood
0.00
N/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.0090.04% Upside
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.50
Moderate Buy$24.0022.64% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$12.00-6.54% Downside

Current Analyst Ratings Breakdown

Latest CORBF, LFMD, FLGT, and CSTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $18.00
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/6/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
5/5/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00
4/30/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/28/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$30.00
(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CORBF
Global Cord Blood
$196.12M0.93$1.07 per share1.40N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$332.07M1.69$1.00 per share19.47$16.28 per share1.20
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$283.47M2.10N/AN/A$36.92 per share0.53
LifeMD, Inc. stock logo
LFMD
LifeMD
$212.45M2.75N/AN/A($0.09) per share-142.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CORBF
Global Cord Blood
$79.04MN/A0.00N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)
LifeMD, Inc. stock logo
LFMD
LifeMD
-$18.88M-$0.34N/A107.00N/A-4.58%N/A-15.19%8/6/2025 (Estimated)

Latest CORBF, LFMD, FLGT, and CSTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04$0.01+$0.05$0.01$62.47 million$65.70 million
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
5/2/2025Q1 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CORBF
Global Cord Blood
N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CORBF
Global Cord Blood
N/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
9.37
9.19
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.32
6.32
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.82
0.77

Institutional Ownership

CompanyInstitutional Ownership
CORBF
Global Cord Blood
N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%

Insider Ownership

CompanyInsider Ownership
CORBF
Global Cord Blood
0.50%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.50%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
31.76%
LifeMD, Inc. stock logo
LFMD
LifeMD
18.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CORBF
Global Cord Blood
1,200121.55 millionN/ANot Optionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million27.00 millionOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31330.44 million20.78 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23045.45 million37.09 millionOptionable

Recent News About These Companies

LifeMD (NASDAQ:LFMD) Shares Down 5% - Here's What Happened
LifeMD: An Overlooked GLP-1 Beneficiary
LifeMD: Getting Frothy
LifeMD (NASDAQ:LFMD) Sets New 1-Year High - What's Next?
LifeMD (NASDAQ:LFMD) Shares Gap Up After Analyst Upgrade
LifeMD (NASDAQ:LFMD) Price Target Raised to $18.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Global Cord Blood NYSE:CORBF

$1.50 0.00 (0.00%)
As of 06/25/2025 02:19 PM Eastern

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$19.47 +0.31 (+1.62%)
Closing price 06/25/2025 04:00 PM Eastern
Extended Trading
$19.47 0.00 (0.00%)
As of 06/25/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$19.57 +0.05 (+0.26%)
Closing price 06/25/2025 04:00 PM Eastern
Extended Trading
$19.45 -0.12 (-0.63%)
As of 06/25/2025 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$12.84 -1.21 (-8.61%)
Closing price 06/25/2025 04:00 PM Eastern
Extended Trading
$12.88 +0.04 (+0.31%)
As of 06/25/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.